In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary ...

Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the bile ducts of the liver. Researchers ...

Primary biliary cirrhosis (PBC) is a chronic, cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts, resulting in chronic cholestasis, portal inflammation ...

The association between celiac disease and primary biliary cirrhosis is well established. The breakdown of gut–liver axis equilibrium plays a central role in the development of immune disorders ...

The global primary biliary cholangitis therapeutics market size was valued at US$732.5 million in 2023 and is projected to reach US$1358.1 billion by 2032, growing at a CAGR of 7.1% from 2024 to 2032.

Intercept already sells a formulation of the drug under the Ocaliva brand name for primary biliary cirrhosis and cholangitis, with US revenues of around $260 million last year and another $100 ...

These include different types of cholangitis (inflammation of the bile ducts), human immunodeficiency virus (HIV), and primary biliary cirrhosis (a chronic liver disease). In addition to taking ...

and alpha 1 antitrypsin deficiency non-alcoholic fatty liver disease primary biliary cirrhosis (PBC) Smoking increases your risk of many different cancers, including liver cancer. In the UK, 20 out of ...

or congenital biliary anomalies, is a common devastating liver dysfunction, resulting in liver toxicity, cirrhosis, and eventually hepatic failure. Therapy for obstructive cholestasis is mainly ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...